Compliance Under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Annual Report for The Financial Year 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has filed its 31st Annual Report for FY 2024-25 with BSE in compliance with SEBI LODR Regulation 34. The 31st Annual General Meeting (AGM) is scheduled for Wednesday, December 31, 2025, at 09:00 AM in physical mode at the company's registered office in Jhajjar, Haryana. The AGM notice includes resolutions for adoption of audited financials, re-appointment of Ms. Parul Agrawal (Non-Executive Director) who retires by rotation, appointment of M/s SBR & Co. LLP as Secretarial Auditors for a 5-year term (FY 2025-26 to FY 2029-30), and regularization of Mr. Yogainder Kumar Gupta as Independent Director for 5 years from May 30, 2025. A special resolution seeks re-appointment of Mr. Yogesh Agrawal as Chairman and Managing Director for 5 years from September 7, 2025, with a consolidated salary of Rs. 2,50,000 per month. Another special resolution proposes adding new clauses (15-21) to the Object Clause of the MOA, expanding the company's business scope into genomics, AI-based diagnostics, biotech R&D, gene editing, and related areas.
Routine annual compliance filing with no immediate effect on share price. However, the MOA amendment signals a strategic broadening of business into AI-driven genomics and diagnostics, while management continuity is maintained through the MD's re-appointment. Shareholders should review the AGM resolutions, as the expanded object clause gives the company wider operational flexibility.